Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology
Merck Serono and Illumina, Inc., announced a collaboration to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies.
Under the terms of the agreement, Merck Serono and Illlumina will work together to develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting. Illumina’s successful regulatory track record was an important consideration in the collaboration, as next-generation sequencing platforms cleared by a regulatory agency could accelerate the development of an assay and facilitate the registration of a companion diagnostic.
“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, Head of Global Business Development at Merck Serono. “This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology.”
The collaboration will include development of the diagnostic, worldwide regulatory approvals, and global commercialization.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Carl Zeiss Obtains Licence from University of California for Illumination Technique
Canbex Therapeutics receives £1.75 million Translation Award from the Wellcome Trust
Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset
A new mechanism protects against cancer cell migration and neuron hyperexcitability
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Asterion Raises £355k Funding to Progress Novel Therapies for Hormone Related Diseases
Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
